Intellectual property is one of the most important assets a life sciences company has. As such, when engaging team members in the buying, selling, licensing, distribution or franchising of IP, the need to engage in a meticulous and strategically timed IP due diligence review is essential to protecting the investments that are made and to preventing a disappointing or even disastrous outcome.
ACI’s 4th Annual Life Sciences IP Due Diligence Summit is devoted to providing corporate and IP counsel with expert strategies for assessing, valuing and commercializing IP assets when conducting strategic IP due diligence which is essential to nearly every corporate transaction. A group of esteemed speakers will provide insights on what to look for during the due diligence process, when to report findings, how to communicate effectively within and across teams, and when to adjust expectations and decisions as the process proceeds.
In addition, this year’s event will shed light on COVID-19’s impact on biopharma deal-making, patent strategies and valuation of IP assets, as well as how to effectively and successfully conduct a virtual IP due diligence analysis.
A frontline faculty of senior industry insiders – including senior executives and corporate counsel from the likes of Akebia Therapeutics, Boehringer Ingelheim, Eli Lilly and Company, Gilead Sciences, Merck, Novartis, Sanofi, Takeda and many others — will share best practices to enable your company to advance its key business development strategies, and to turn a good deal into a great investment.
Register to secure a spot at this year’s virtual event by clicking here.